On Monday, Shares of Intec Pharma Ltd (NASDAQ:NTEC), added 3.70% and now trading at $5.60 in the current trading session. The current trading range of the stock ranges between $5.20 and $5.70.
Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, recently declared the appointment of Jeffrey A. Meckler as Vice Chairman of its Board of Directors, effective right away.
“We are delighted to welcome Jeff to the Intec Board,” commented John W. Kozarich, Ph.D., Chairman of the Board of Intech Pharma. “Jeff’s rich industry experience and insights into corporate development strategies are renowned in the industry. Our innovative drug delivery platform technology will benefit greatly from Jeff’s efforts. In addition, his joining the Intec Pharma team dovetails with our aim to extend the U.S. and global footprint of Intec and enhance the broader recognition of our technology.”
Mr. Meckler brings to Intec Pharma more than 25 years of life sciences executive experience. Mr. Meckler spent more than 17 years at Pfizer, where he held leadership positions in corporate planned planning, acquisitions and business development, market research, manufacturing systems and sales operations analysis. Most recently, Mr. Meckler was Chief Executive Officer of Cocrystal Pharma, Inc. Formerly, Mr. Meckler was a director of QLT Inc., and at first the principal executive officer during its transformation into an orphan drug company. He has served on numerous corporate boards and is presently a director of Retrophin, Inc.
“I am eager to be joining the Intec Pharma team,” said Jeffrey Meckler. “It will be exciting to assist maximize the potential of the Accordion Pill technology and its various therapeutic programs, such as the Parkinson’s disease program. I look forward to working with my fellow directors and the administration team to assist grow Intec Pharma.”
Mr. Meckler earned his J.D. from Fordham University School of Law and is admitted to the New York Bar. He earned an M.S. in Industrial Administration and a B.S. in Industrial Administration from Carnegie Mellon University.
Analyst recommendation for this stock stands at 2.00.